CTOs on the Move

Zenflow

www.zenflow.com

 
Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign prostatic hyperplasia (BPH). Millions of patients do not see effective relief from drugs, yet decline to undergo an invasive surgical procedure with high risk of side effects such as sexual dysfunction.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.zenflow.com
  • 395 Oyster Point Blvd Suite 501
    South San Francisco, CA USA 94080
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Zenflow raised $24.3M on 04/15/2021

Similar Companies

Ablative Solutions

Ablative Solutions is a clinical-stage medical device start-up that is pioneering the novel approach of Transcatheter Perivascular Alcohol Denervation for the treatment of hypertension.

Conventus Orthopaedics

Taking its name from the Latin word for coming together or union, Conventus Orthopaedics is focused on creating less invasive solutions to fractures in and around joints. The company is dedicated to working with surgeons to improve healing and enable their patients return to normal activity. Specialties

Belmont Instruments

Belmont Instruments is a Billerica, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pentax Vision

Pentax Vision is a Hopkins, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NOWDiagnostics

NOWDiagnostics Inc., based in Springdale, Ark., is a leader in innovative diagnostics testing. Its ADEXUSDx™ product line features a lab at your fingertip, using only a single drop of blood to test for a variety of common conditions, illnesses and diseases with results in a matter of minutes. By eliminating the need to send tests to off-site laboratories, NOWDiagnostics has the potential to decrease by days the waiting period to determine test results. The company is currently offering an hCG (pregnancy) test in the United States and Europe, and two cardiac (heart attack) tests and three toxicology tests in Europe. Additional tests are in the development pipeline, including sexually transmitted diseases, more cardiac (heart attack), food intolerances, common infectious diseases and a variety of screening tests.